CompanyMLTXNasdaqZug, V8

MoonLake Immunotherapeutics AG

Clinical-stage biotech company developing SLK, a tri-specific Nanobody inhibiting IL-17A and IL-17F, for inflammatory skin and joint diseases including hidradenitis suppurativa.

Stories only

SEC EDGAR ClinicalTrials.gov euclinicaltrials.eu

8-KSep 30Latest SEC filing

Sep 10Latest story

September 2026

MoonLake posts Phase 2 results for sonelokimab in psoriatic arthritis and hidradenitis suppurativa

Sep 10Weekly roundup, 2 itemsMoonLake Immunotherapeutics AG sonelokimab

August 2026

MoonLake reports positive Phase 3 IZAR-1 results in psoriatic arthritis, Q2 2026 earnings

Aug 10Quarterly updateMoonLake Immunotherapeutics AG sonelokimab